A detailed history of Trexquant Investment LP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 25,066 shares of AKRO stock, worth $820,410. This represents 0.01% of its overall portfolio holdings.

Number of Shares
25,066
Previous 24,651 1.68%
Holding current value
$820,410
Previous $578,000 24.39%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.45 - $29.34 $8,901 - $12,176
415 Added 1.68%
25,066 $719,000
Q2 2024

Aug 13, 2024

BUY
$18.31 - $24.62 $451,359 - $606,907
24,651 New
24,651 $578,000
Q3 2023

Nov 13, 2023

BUY
$41.19 - $52.25 $1.34 Million - $1.7 Million
32,547 Added 323.11%
42,620 $2.16 Million
Q2 2023

Aug 11, 2023

BUY
$36.89 - $56.88 $371,592 - $572,952
10,073 New
10,073 $470,000
Q4 2022

Feb 13, 2023

SELL
$33.44 - $54.8 $613,189 - $1 Million
-18,337 Reduced 44.54%
22,830 $1.25 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $240,128 - $805,554
23,658 Added 135.12%
41,167 $1.4 Million
Q2 2022

Aug 11, 2022

BUY
$8.0 - $15.01 $44,744 - $83,950
5,593 Added 46.94%
17,509 $165,000
Q1 2022

May 13, 2022

BUY
$12.97 - $22.26 $154,550 - $265,250
11,916 New
11,916 $169,000
Q2 2021

Aug 12, 2021

SELL
$24.81 - $32.35 $206,989 - $269,896
-8,343 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$24.04 - $34.19 $2,620 - $3,726
-109 Reduced 1.29%
8,343 $242,000
Q4 2020

Feb 11, 2021

BUY
$25.12 - $29.89 $47,326 - $56,312
1,884 Added 28.68%
8,452 $218,000
Q3 2020

Nov 06, 2020

BUY
$30.79 - $39.92 $202,228 - $262,194
6,568 New
6,568 $202,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.52B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Trexquant Investment LP Portfolio

Follow Trexquant Investment LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

News

Stay updated on Trexquant Investment LP with notifications on news.